



# List of guidance from ECDC and recent publications on COVID-19

## COVID-19 Digest

### ECDC Outputs

#### Recent publications

**Assessment of the current SARS-CoV-2 epidemiological situation in the EU/EEA, projections for the end-of-year festive season and strategies for response, 17<sup>th</sup> update** Rapid Risk Assessment – 24 Nov [Read more »](#)

*Related video statement by the ECDC Director* [Link](#)

**Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA** Technical Report – 11 Nov [Read more »](#)

**Contact tracing: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases in the European Union – fourth update** Technical Report – 28 Oct [Read more »](#)

**Options for the use of rapid antigen tests for COVID-19 in the EU/EEA – first update** Technical Report – 26 Oct [Read more »](#)

**COVID-19 surveillance guidance – Transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens** Technical Report – 18 Oct [Read more »](#)

**Facilitating COVID-19 vaccination acceptance and update in the EU/EEA** Technical Report – 15 Oct [Read more »](#)

**All ECDC scientific advice on coronavirus** [Read more »](#)

#### Situation updates on COVID-19

**COVID-19 situation update for the EU/EEA:** Includes an update on the number of cases and deaths and geographical distribution of 14-day notification rates for the EU/EEA. [Read more »](#)

**COVID-19 situation update worldwide:** Includes an update on the number of cases and deaths and geographical distribution of 14-day notification rates worldwide. [Read more »](#)

**COVID-19 country overview:** Provides an overview of the evolving epidemiological situation for the EU/EEA (including case/death notification rates, testing rates, test positivity, hospital and ICU occupancy/capacity per country). [Read more »](#)

**Surveillance report on COVID-19:** Includes information on severity and risk groups most affected for the EU/EEA, as well as information on The European Surveillance System (TESSy) data quality and descriptions about national surveillance systems. [Read more »](#)

**Situation dashboard:** Interactive map with the latest available data on COVID-19 (worldwide). [Read more »](#)

**Vaccine tracker:** Real time data on national vaccine doses distribution and vaccine update within EU/EEA countries. [Read more »](#)

**Vaccine roll-out overview report:** This report complements the Vaccine tracker and provides an overview of the progress in the roll-out of COVID-19 vaccines in adults (aged 18 years and above) across EU/EEA Member States, incl. vaccine doses distributed and administered. [Read more »](#)

**Maps in support of the Council Recommendation** on a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic in the EU/EEA. These maps are published every Thursday based on a number of different indicators. [Read more »](#)

**Response Measures Database** of ECDC and the Joint Research Centre (JRC) of the European Commission is a regularly updated archive of non-pharmaceutical interventions introduced by 30 countries in the EU/EEA. [Read more »](#)

## Updates on SARS-CoV-2 variants

**SARS-CoV-2 variants of concern:** Overview of the different variants that are currently being considered of concern and of interest as assessed by ECDC. [Read more »](#)

**Variants of concern.** The ECDC country overview includes an own section on variants of concern. It includes e.g. a map of sequencing volume, variant data table and weekly variant distribution by country. [Read more »](#)

**Dashboard on SARS-CoV-2 variants.** This dashboard provides an overview of the proportion of variants of concern and variants of interest in EU/EEA Member States together with sequencing volumes and complements the ECDC country overview report. [Read more »](#)

## Download data on COVID-19

Much of ECDC's data can be downloaded from its website. This for instance includes, but is not limited to, reported number of cases and deaths, 14-day case notification rates, ICU and hospital admissions/occupancy, testing rates/positivity, vaccination data and response measures implemented in EU/EEA countries. [Link to downloadable data»](#)

## Infographics, Videos, Webinars and more

**Infographics and leaflets about COVID-19** – Infographics, leaflets and posters on COVID-19. [Read more »](#)

**Videos on COVID-19** – What do we know about the COVID-19. [Read more »](#)

**ECDC Virtual Academy (EVA)** – COVID-19 Micro learning for public health professionals. [Read more »](#)

**Online micro learning activities on non-pharmaceutical countermeasures in relation to COVID-19.** E-learning course. [Read more »](#)

## Other ECDC Outputs

**ECDC website on COVID-19** – [Read more »](#)

**ECDC case definition for COVID-19.** [Read more »](#)

**Find the latest evidence on:**

- [Coronaviruses](#)
- [Risk factors and risk groups](#)
- [Transmission of COVID-19](#)
- [COVID-19 infection](#)
- [Clinical characteristics of COVID-19](#)
- [Diagnostic testing and screening for SARS-CoV-2](#)
- [Immune responses and immunity to SARS-CoV-2](#)
- [Treatment and pharmaceutical prophylaxis](#)
- [COVID-19 vaccines](#)

**Surveillance definitions for COVID-19.** High risk exposure/close contact, transmission status, death due to COVID-19. [Read more »](#)

**Testing strategies for SARS-CoV-2** - Patients requiring diagnostic testing. [Read more »](#)

**Preparedness for COVID-19** – Publications and guidance for preparedness planning. [Read more »](#)

**Prevention and control of COVID-19** – how to protect yourself, risk groups, COVID-19 vaccination, patient and case management. [Read more »](#)

**Q & A on COVID-19** – Questions and answers. [Read more »](#)

## Recent peer-reviewed publications

Disclaimer: In view of the large number of COVID-19 related publications, this list is compiled based on a rapid review of titles and abstracts and subjective selection of peer-reviewed articles and does not include a qualitative assessment or critical appraisal of the evidence.

1. Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020 *Eurosurveillance* [Read more »](#)
2. A wastewater-based epidemiology tool for COVID-19 surveillance in Portugal *Sci Total Environ* [Read more »](#)
3. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic *Lancet* [Read more »](#)
4. Decrease in community antibiotic consumption during the COVID-19 pandemic, EU/EEA, 2020 *Eurosurveillance* [Read more »](#)
5. Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021 *Eurosurveillance* [Read more »](#)
6. Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older *JAMA* [Read more »](#)
7. Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill-An interim analysis of a nationwide cohort study *PLoS One* [Read more »](#)
8. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study *Lancet* [Read more »](#)
9. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial *Lancet* [Read more »](#)
10. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial *Lancet Infect Dis* [Read more »](#)
11. What influences people's responses to public health messages for managing risks and preventing infectious diseases? A rapid systematic review of the evidence and recommendations *BMJ Open* [Read more »](#)
12. Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol *BMJ Open* [Read more »](#)
13. More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A Scoping Review *Front Med* [Read more »](#)
14. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis *BMJ* [Read more »](#)
15. Modelling the effect of a border closure between Switzerland and Italy on the spatiotemporal spread of COVID-19 in Switzerland *Spat Stat* [Read more »](#)

## Additional Resources

### Information from European Institutions, International Organisations and Centres for Disease Control and Prevention

**European Union.** Re-open EU: interactive tool with country information for travel and transportation [Read more »](#)

**European Commission.** Coronavirus response. [Read more »](#)

**European Parliament.** The EU's response to the coronavirus. [Read more »](#)

**EU Healthy Gateways:** [Published guidance and reports for COVID-19](#)

**European Agency for Safety and Health (OSHA).** COVID-19: Resources for the workplace: EU guidance, telework, resources from EU and international organisations. [Read more »](#)

**European Food Safety Authority (EFSA).** COVID-19. [Read more »](#)

**European Medicines Agency (EMA):** Treatments and vaccines for COVID-19. [Latest updates on COVID-19.](#)

**European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).** COVID-19 and drugs. [Read more »](#)

**Health Systems Response Monitor:** [COVID-19 Health System Response Monitor](#) designed in response to the COVID-19 outbreak to collect and organize up-to-date information on how countries are responding to the crisis

**World Health Organization (WHO).** Coronavirus disease (COVID-19) pandemic. [Read more »](#)

**Food and Agriculture Organization of the UN (FAO):** Novel Coronavirus. [Read more »](#)

**African Centres of Disease Control and Prevention.** [Read more »](#)

**Public Health Agency of Canada.** [Read more »](#)

**Chinese Center for Disease Control and Prevention.** [Read more »](#)

**Israel Center for Disease Control, Ministry of Health.** [Read more »](#)

**Ministry of Health of Mexico.** [Read more »](#)

**US Centers for Disease Control and Prevention.** [Read more »](#)

### COVID-19 information pages of EU/EEA Member States



[Austria »](#)



[Belgium »](#)



[Bulgaria »](#)



[Croatia »](#)



[Cyprus »](#)



[Czechia »](#)



[Denmark »](#)



[Estonia »](#)



[Finland »](#)



[France »](#)



[Germany »](#)



[Greece »](#)



[Hungary »](#)



[Iceland »](#)



[Ireland »](#)



[Italy »](#)



[Latvia »](#)



[Liechtenstein »](#)



[Lithuania »](#)



[Luxembourg »](#)



[Malta »](#)



[Netherlands »](#)



[Norway »](#)



[Poland »](#)



[Portugal »](#)



[Romania »](#)



[Slovakia »](#)



[Slovenia »](#)



[Spain »](#)



[Sweden »](#)

## Living Evidence Summaries

**COAP:** [COVID-19 Open Access Project](#) from the Institute of Social and Preventive Medicine ([ISPM](#)). This database is updated daily with published articles from Pubmed and EMBASE and with preprints from medRxiv and bioRxiv.

**COVID-END McMaster Health Forum:** [living evidence syntheses](#) on a variety of topics including efficacy and effectiveness of COVID-19 vaccines in the presence of variants of concern (VOCs).

**EPPI Centre:** [COVID-19](#): a living systematic map of the evidence. Up-to-date map of the current evidence that are partitioned into broad domains for easy exploration.

**NMA initiative:** [Covid-19 – living initiative](#). Living mapping and living systematic review of Covid-19 trials.

**PregCOV-19LSR** by the University of Birmingham. Series of living systematic reviews (LSR) involving pregnant and postnatal women at risk, suspected, and diagnosed to have COVID-19 according to recommended methods. [Read more »](#)

**theBMJ:** [Drug treatments for covid-19](#): living systematic review and network meta-analysis

## Science Updates

**Centre for Evidence-Based Medicine CEBM:** [Oxford COVID-19 Evidence Service](#). Rapid reviews of primary care questions relating to COVID-19.

**Cochrane:** [Cochrane Reviews](#) and related content from the Cochrane Library relating to the COVID-19 pandemic.

**COVID Reference International:** Every day the “Top 10 scientific COVID-19 papers of the day” are presented. Also provides multiple other useful links to literature. [Read more »](#)

**COVID-AMR:** [Peer-reviewed literature](#) on secondary infections, antibiotic chemotherapy and AMR in the context of COVID-19.

**Evidence Aid:** [Evidence Collection](#) on Coronavirus (COVID-19). This evidence collection contains plain-language summaries of high-quality research which are available in English, and translated into French, Spanish, Portuguese, Arabic and Chinese (simplified and traditional).

**Health Information and Quality Authority:** [COVID-19 Publications](#): Clinical evidence summaries and rapid reviews on various different topics.

**LitCovid:** [curated literature hub](#) for tracking up-to-date scientific information about COVID-19. It is the most comprehensive resource on the subject, providing a central access a large number of relevant articles in PubMed. The articles are updated daily and are further categorized by different research topics and geographic locations for improved access.

**US Centers for Disease Control and Prevention:** [COVID-19 Science Updates](#) providing brief summaries of new COVID-19-related studies on many topics, including epidemiology, clinical treatment and management, laboratory science, and modeling. The summaries are released every Tuesday and Friday.

**VA-ESP COVID-19 Reviews:** [U.S. Veterans’ Affairs \(VA\) Evidence Synthesis Program](#) - Inventory of living systematic reviews and ‘rapid reviews’, with a flag for living reviews and for reviews meeting minimum quality standards

**Wolters Kluwer:** [Clinical effectiveness COVID-19 Recourses Available to All](#). View a categorized collection of all UpToDate COVID-19 content including clinical topics, algorithms, patient education and society guideline links.

**World Health Organization:** [COVID-19 Global literature on coronavirus disease](#). Literature database.